Brain

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor…

4 months ago

GoMo Health Launches the Women, Children and Families Engagement Hub to Improve Whole-Family Care and Health Outcomes In Every Life Stage

Holistic engagement programs offer healthcare organizations a scalable solution to support women and families in managing their physical, mental, and…

4 months ago

BestQool Announces Summer Promotion and Fall Refresh with New Logo and BQ60Pro Preview

Summer Appreciation Sales Offers 12% Off All Products NEW YORK, Aug. 15, 2025 /PRNewswire/ -- BestQool , a pioneer manufacturer…

4 months ago

CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Strong cash position of $12.1 million expected to fund operations into the second half of 2026Driving lead program, TPI 287,…

4 months ago

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile Initial…

4 months ago

“I WISH I HAD THIS WHEN I WAS A KID,” MINDIFUL® MOVEMENT PUTS KIDS FIRST

The most magical part? It's for everyone. HOLLYWOOD, Calif., Aug. 14, 2025 /PRNewswire/ -- Mindiful® is leading a movement to…

4 months ago

CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

- Live video webcast on Tuesday, August 19th at 2:40 PM ET HOUSTON, TX / ACCESS Newswire / August 14,…

4 months ago

Hemostemix’s Expands its Marketing Team Focused on Sales in Florida

Calgary, Alberta--(Newsfile Corp. - August 14, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), an autologous stem cell…

4 months ago

Last patient visit completed on schedule in Phase 1b clinical trial of HER-096 for Parkinson’s disease

Patient visits are now complete in the final cohort of Phase 1b trial, consisting of Parkinson’s disease patients receiving 300…

4 months ago